MARICQ, 1991, Science, 254, 432, 10.1126/science.1718042
DAVIES, 2006, Alcohol. Clin. Exp. Res., 30, 349, 10.1111/j.1530-0277.2006.00023.x
MIYAKE, 1995, Mol. Pharmacol., 48, 407
FIEBICH, 2004, Scand. J. Rheumatol., 33, 9, 10.1080/03009740410006952
DAVIES, 1999, Nature, 397, 359, 10.1038/16941
SUDWEEKS, 2002, J. Physiol., 544, 715, 10.1113/jphysiol.2002.029736
MORALES, 2002, J. Neurosci., 22, 6732, 10.1523/JNEUROSCI.22-15-06732.2002
NIESLER, 2003, Gene, 310, 101, 10.1016/S0378-1119(03)00503-1
TZVETKOV, 2007, Gene, 386, 52, 10.1016/j.gene.2006.08.002
KARNOVSKY, 2003, Gene, 319, 137, 10.1016/S0378-1119(03)00803-5
VAN HOOFT, 1998, Proc. Natl. Acad. Sci. USA, 95, 11456, 10.1073/pnas.95.19.11456
MIQUEL, 2002, Eur. J. Neurosci., 15, 449, 10.1046/j.0953-816x.2001.01872.x
TECOTT, 1993, Proc. Natl. Acad. Sci. USA, 90, 1430, 10.1073/pnas.90.4.1430
KIA, 1995, Neuroreport, 6, 257, 10.1097/00001756-199501000-00008
HUANG, 2004, Brain Res., 1028, 5, 10.1016/j.brainres.2004.09.009
GALLIGAN, 2002, Neurogastroenterol. Motil., 14, 611, 10.1046/j.1365-2982.2002.00363.x
BHATTACHARYA, 2004, J. Neurosci., 24, 5537, 10.1523/JNEUROSCI.5658-03.2004
THOMPSON AJ, LUMMIS SCR: The relationship between structure and function in the 5-HT3receptor: the transmembrane domain. In:Biological and Biophysical Aspects of Ligand-Gated Ion Channel Receptor Superfamilies. Arias HR (Ed.) Research Signpost, Kerala, India (2006):155-170.
REEVES, 2002, Mol. Membr. Biol., 19, 11, 10.1080/09687680110110048
BREJC, 2001, Nature, 411, 269, 10.1038/35077011
BOUZAT, 2004, Nature, 430, 896, 10.1038/nature02753
THOMPSON, 2005, J. Biol. Chem., 280, 20476, 10.1074/jbc.M413610200
REEVES, 2003, Biophys. J., 84, 2338, 10.1016/S0006-3495(03)75039-5
YAN, 2005, Mol. Pharmacol., 68, 365, 10.1124/mol.105.011957
MAKSAY, 2003, J. Recept. Signal Transduct. Res., 23, 255, 10.1081/RRS-120025568
THOMPSON AJ, ZHANG L, LUMMIS SCRL: The 5-HT3receptor. In:The serotonin receptors: from molecular pharmacology to human therapeutics. Roth BL (Ed.) Humana Press, New Jersey, USA (2006):439-457.
THOMPSON, 2006, Curr. Pharm. Des., 12, 3615, 10.2174/138161206778522029
MIYAZAWA, 2003, Nature, 424, 949, 10.1038/nature01748
REEVES, 2001, J. Biol. Chem., 276, 42035, 10.1074/jbc.M106066200
KANEEZ, 2004, J. Biomed. Biotechnol., 2004, 10, 10.1155/S1110724304302020
LUMMIS, 2005, Nature, 438, 248, 10.1038/nature04130
THOMPSON, 2003, Br. J. Pharmacol., 140, 359, 10.1038/sj.bjp.0705424
DAS, 2005, J. Pharmacol. Exp. Ther., 314, 320, 10.1124/jpet.104.080325
STEVENS, 2005, J. Pharmacol. Exp. Ther., 314, 338, 10.1124/jpet.105.085076
SESSOMS-SIKES, 2003, J. Pharmacol. Exp. Ther., 306, 595, 10.1124/jpet.103.050542
HU, 2006, Br. J. Pharmacol., 148, 88, 10.1038/sj.bjp.0706685
SOLT, 2005, J. Pharmacol. Exp. Ther., 315, 771, 10.1124/jpet.105.090621
HUSSY, 1994, J. Physiol., 481, 311, 10.1113/jphysiol.1994.sp020441
KELLEY, 2003, Nature, 424, 321, 10.1038/nature01788
QUIRK, 2004, J. Neurosci. Res., 77, 498, 10.1002/jnr.20185
MONK, 2004, Biochem. Pharmacol., 68, 1787, 10.1016/j.bcp.2004.06.034
CAMPIANI, 1997, J. Med. Chem., 40, 3670, 10.1021/jm970376w
GLENNON, 1992, Pharmacol. Biochem. Behav., 41, 5, 10.1016/0091-3057(92)90111-R
HAUS, 2004, Scand. J. Rheumatol., 33, 12, 10.1080/03009740410006961
KING FD, JONES BJ, SANGER GJ: In:5-Hydroxytryptamine-3 Receptor Antagonist. King FD, Jones BJ, Sanger GJ (Eds.), CRC Press, Florida, USA (1994):155-181.
AAPRO, 2006, Ann. Oncol., 17, 1441, 10.1093/annonc/mdl137
FUJII, 1998, Acta Anaesthesiol. Scand., 42, 312, 10.1111/j.1399-6576.1998.tb04922.x
EINARSON, 2004, Br. J. Gynecol., 111, 940, 10.1111/j.1471-0528.2004.00236.x
MINAMI, 2003, Pharmacol. Ther., 99, 149, 10.1016/S0163-7258(03)00057-3
TREMBLAY, 2003, J. Clin. Oncol., 21, 2147, 10.1200/JCO.2003.05.164
BRADY, 2001, Neuropharmacology, 41, 282, 10.1016/S0028-3908(01)00074-0
DUBIN, 1999, J. Biol. Chem., 274, 30799, 10.1074/jbc.274.43.30799
KAISER, 2004, Pharmacogenetics, 14, 271, 10.1097/00008571-200405000-00001
GUTIERREZ, 2002, Schizophr. Res., 58, 93, 10.1016/S0920-9964(02)00205-0
PIPER, 2002, Anesth. Analg., 94, 106, 10.1213/00000539-200201000-00020
PIPER, 2002, Anasthesiol. Intensivmed. Notfallmed. Schmerzther., 37, 528, 10.1055/s-2002-33767
GRALLA, 1999, J. Clin. Oncol., 17, 2971, 10.1200/JCO.1999.17.9.2971
CARLISLE, 2006, Cochrane Database Syst. Rev., 3, CD004125
JOHNSON, 2000, JAMA, 284, 963, 10.1001/jama.284.8.963
MERTZ, 2000, Gastroenterology, 118, 842, 10.1016/S0016-5085(00)70170-3
10.1046/j.1365-2036.1998.00375.x
CROWELL, 2001, Am. J. Manag. Care, 7, S252
JONES, 1999, Aliment. Pharmacol. Ther., 13, 1419, 10.1046/j.1365-2036.1999.00678.x
2002, Lotronex (alosetron hydrochloride) prescribing information
ANDRESEN, 2004, Drug Saf., 27, 283, 10.2165/00002018-200427050-00001
MAYER, 2003, Expert Opin. Pharmacother., 4, 2089, 10.1517/14656566.4.11.2089
BERARDI, 2004, J. Am. Pharm. Assoc, 44, 41, 10.1331/154434504322713228
TALLEY, 2002, Expert Opin. Emerg. Drugs, 7, 91, 10.1517/14728214.7.1.91
HADLEY, 2005, Am. Fam. Physician, 72, 2501
GREENSHAW, 1997, Drugs, 53, 20, 10.2165/00003495-199753010-00003
GADDUM, 1954, Br. J. Pharmacol, 9, 240
WOOLEY, 1954, Proc. Natl. Acad. Sci. USA, 40, 228, 10.1073/pnas.40.4.228
ADLER, 2005, Am. J. Psychiatry, 162, 386, 10.1176/appi.ajp.162.2.386
KOIKE, 2005, Schizophr. Res., 76, 67, 10.1016/j.schres.2004.12.016
NIESLER, 2001, Pharmacogenetics, 11, 21, 10.1097/00008571-200102000-00003
THOMPSON, 200, J. Mol. Neurosci.
KURZWELLY, 2004, Pharmacogenetics, 14, 165, 10.1097/00008571-200403000-00004
KELLEY, 2003, Eur. J. Pharmacol., 461, 19, 10.1016/S0014-2999(02)02960-6
BHATNAGAR, 2004, Behav. Brain Res., 153, 527, 10.1016/j.bbr.2004.01.018
BARNES, 1992, Eur. J. Pharmacol., 218, 15, 10.1016/0014-2999(92)90142-Q
EISENSAMER, 2005, J. Neurosci., 25, 10198, 10.1523/JNEUROSCI.2460-05.2005
LUMMIS, 1997, Neuropharmacology, 36, 665, 10.1016/S0028-3908(97)00054-3
RAMMES, 2004, Mol. Psychiatry, 9, 846, 10.1038/sj.mp.4001490
EISENSAMER, 2003, Mol. Psychiatry, 8, 994, 10.1038/sj.mp.4001314
OLIVIER, 2000, Eur. Neuropsychopharmacol., 10, 5, 10.1016/S0924-977X(99)00065-6
OLDEN, 2005, CNS Spectr., 10, 891, 10.1017/S1092852900019866
HARRELL, 2003, Learn. Mem., 10, 410, 10.1101/lm.56103
PRESTON GC:5-HT3Antagonists and dosorders of cognition. In:Recent Advances in the treatment of neurodegenerative diorders and cognitive dysfunction. Racagni G, Brunello N, Langer SZ (Eds.), International Academy of Biomedical Drug Research, Karger, Basel, Switzerland (1994) 7:89-93.
IIDAKA, 2005, J. Neurosci., 25, 6460, 10.1523/JNEUROSCI.5261-04.2005
NIESLER, 2001, Pharmacogenetics, 11, 471, 10.1097/00008571-200108000-00002
BUHOT, 2000, Ann. Med., 32, 210, 10.3109/07853890008998828
HODGE, 1993, Alcohol, 10, 191, 10.1016/0741-8329(93)90034-L
DAWES, 2005, Addict. Behav., 30, 1630, 10.1016/j.addbeh.2005.07.004
PELTIER, 1991, Pharmacol. Biochem. Behav., 39, 133, 10.1016/0091-3057(91)90410-4
10.1007/s00213-002-1002-9
POTVIN, 2003, Int. Clin. Psychopharmacol., 18, 121
HAYRAPETYAN, 2005, Brain Res. Mol. Brain Res., 142, 146, 10.1016/j.molbrainres.2005.09.011
FARIS, 2006, J. Affect. Disord., 92, 79, 10.1016/j.jad.2005.12.047
FRANK, 2001, Int. J. Eat. Disord., 30, 57, 10.1002/eat.1054
SCHWORER, 1993, Clin. Investig., 71, 659, 10.1007/BF00184497
SCHWORER, 1995, Pain, 61, 5, 10.1016/0304-3959(94)00145-5
O’DONOHUE, 2005, Aliment. Pharmacol. Ther., 21, 1041, 10.1111/j.1365-2036.2005.02430.x
WEISSHAAR, 2003, Clin. Nephrol., 59, 124, 10.5414/CNP59124
WEISSHAAR, 2004, Exp. Dermatol., 13, 298, 10.1111/j.0906-6705.2004.00184.x
WEISSHAAR, 2003, Acta Derm. Venereol. Suppl., 213, 5, 10.1080/00015555-0369
KHAN, 1999, Biochem. J., 344, 199, 10.1042/bj3440199
PICHE, 2005, Gut, 54, 1169, 10.1136/gut.2004.055251
THE, 2003, Neth J. Med., 61, 285
STRATZ, 2001, Drugs Exp. Clin. Res., 27, 113
SPATH, 2004, Scand. J. Rheumatol., 33, 267, 10.1080/03009740410005818
MULLER, 2004, Scand. J. Rheumatol., 33, 44, 10.1080/03009740410007032
STRATZ, 2004, Scand. J. Rheumatol., 33, 76, 10.1080/03009740410007113
SAMBORSKI, 2004, Scand. J. Rheumatol., 33, 51, 10.1080/03009740410007050
STRATZ, 2003, Schmerz, 17, 200, 10.1007/s00482-003-0219-9
RIERING, 2004, Scand. J. Rheumatol., 33, 19, 10.1080/03009740410006970
GIORDANO, 2004, Pain Physician, 7, 141, 10.36076/ppj.2004/7/141
DEVLIN, 1999, Rheumatology, 38, 280, 10.1093/rheumatology/38.3.280
SANDRINI, 2002, Pharmacology, 65, 193, 10.1159/000064343
SANDRINI, 2003, Inflamm. Res., 52, 347, 10.1007/s00011-003-1185-5
PICKERING, 2006, Clin. Pharmacol. Ther., 79, 371, 10.1016/j.clpt.2005.12.307
BALLESTERO, 2005, Mol. Pharmacol., 68, 822, 10.1124/mol.105.014431
SIEB, 1996, Brain Res., 712, 179, 10.1016/0006-8993(95)01349-0
BROUGHMAN, 2004, Am. J. Physiol. Cell Physiol., 286, C1312, 10.1152/ajpcell.00426.2002
BROUGHMAN, 2002, J. Membr. Biol., 190, 93, 10.1007/s00232-002-1027-3
LUMMIS, 1990, Eur. J. Pharmacol., 189, 223, 10.1016/0922-4106(90)90026-T
DOWNIE, 1994, Neuropharmacology, 33, 473, 10.1016/0028-3908(94)90078-7
LUMMIS, 1993, Eur. J. Pharmacol., 243, 7, 10.1016/0014-2999(93)90160-J
HOPE, 1996, Br. J. Pharmacol., 118, 1237, 10.1111/j.1476-5381.1996.tb15529.x
STEWARD, 1995, Br. J. Pharmacol., 116, 1781, 10.1111/j.1476-5381.1995.tb16663.x
PETERS, 1993, Br. J. Pharmacol., 110, 665, 10.1111/j.1476-5381.1993.tb13863.x
WONG, 1995, Br. J. Pharmacol., 114, 851, 10.1111/j.1476-5381.1995.tb13282.x
BOEIJINGA, 1992, Eur. J. Pharmacol., 219, 9, 10.1016/0014-2999(92)90573-M
KATAYAMA, 1997, Jpn. J. Pharmacol., 73, 357, 10.1254/jjp.73.357
CLAYTON, 1999, Neurogastroenterol. Motil., 11, 207, 10.1046/j.1365-2982.1999.00148.x
AKUZAWA, 1998, Jpn. J. Pharmacol., 78, 381, 10.1254/jjp.78.381
CAPPELLI, 2005, J. Med. Chem., 48, 3564, 10.1021/jm0493461
HAGIHARA, 1994, Eur. J. Pharmacol., 271, 159, 10.1016/0014-2999(94)90276-3
VENKATARAMAN, 2002, BMC Biochem., 3, 16, 10.1186/1471-2091-3-16
VAN WIJNGAARDEN, 1993, J. Med. Chem., 36, 3693, 10.1021/jm00075a026
